Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Brenda L. Greer who wrote (70)	3/5/1998 7:49:00 PM
From: Meisterama	Respond to of 2887

If you're are going to talk about stocks other than ABMI on this board, please reference that fact in your opening line so the rest of us can skip the post. It's hard enough to find time to read all the RELEVANT posts when following several boards.

To: Brenda L. Greer who wrote (70)	3/5/1998 8:19:00 PM
From: Ray Tarke	Read Replies (1) \| Respond to of 2887

Brenda, ABMI has what it takes to be your all-time winner!! You cannot go wrong at this prices, I also bought today. R.T

To: Brenda L. Greer who wrote (70)	3/7/1998 3:32:00 PM
From: Aishwarya	Respond to of 2887

I know Brenda and i would not be in this one if it were not for you: THERE ARE A LOT OF BIG BOYS RIDING THE COATTAILS OF "STENT MANIA", so are we at the cutting edge of Interventional Cardiology ? Stents have revolutionized the treatment of atherosclerosis resulting in a commercial bonanza for many companies. "Stent mania" will remain a potent driver of the interventional cardiology field and of the medical devices industry for at least 10 years. Because of intensifying competition among stent manufacturers overseas and Johnson & Johnson's,Guidant and Baxters virtual monopoly in the U.S., dont you all think the best way for investors to play the stenting phenomenon right now is not through the stent manufacturers themselves, but through companies with proprietary technologies that are applicable to a wide range of stent procedures - regardless of which brand of stent is being used. ABMI stands to gain a lot as stent utilization continues to grow. If It's a Tube, Stent It! Stents are tiny scaffolding devices that are used to prop open the tubular structures of the body. Theoretically, stents can be used to create or maintain an opening in any tubular structure within the body that has become narrowed or blocked due to disease or injury - including the esophagus, the bile duct, the urethra, and the blood vessels. As a Johnson & Johnson executive said, "The human body is a big series of tubes just waiting to be stented." Stents have had their greatest impact in the field of interventional cardiology. They have become indispensable in the treatment of atherosclerosis because they currently offer the most effective way to keep blood vessels open once the plaque has been treated. In other words, stents are the only proven way to reduce the incidence of reclosure of the vessel, or restenosis - a medically and financially costly complication of angioplasty. Although the absolute number of stent procedures is likely to grow each year through the end of the decade. The company faces a much larger opportunity in the delivery of their flexible stents - not only its own but those of dozens of other manufacturers for whom they will manufacture as orders may be subcontracted. If all goes well ABMI ould be making some real good cash by next year end as it takes time to penetrate markets. Hey guys check this website out. Its pretty cool. unmc.edu Regards, Sri.